Program
AQUA07
A development code.
In Hoffmann-La Roche's pipeline, allosteric ALK inhibitor
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hoffmann-La Roche.
Furthest: phase 1, since May 14, 20261 company-led study, 1 open or runningNext primary completion: Aug 31, 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 1since May 14, 2026 | May 14, 2026 | Aug 31, 2030phase 1 · NCT07617337 |
- Named in Hoffmann-La Roche’s own pipeline as
CHU AQUA07 allosteric ALK inhibitor
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2026First study: phase 1 study in ALK Positive Non-small Cell Lung CancerFirst studyNCT07617337 · 102 planned · United States, Japan
Ahead
- Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerNCT07617337
TargetBeta
“allosteric ALK inhibitor”the company's pipeline, read by Claude · source
Other programs on ALK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| lorlatinibrule | Pfizer | phase 4 | 20 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| ensartinibrule | Betta Pharmaceuticals | phase 3 | 12 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| neladalkib | GlaxoSmithKline | phase 3 | 2 |
| Foritinib Succinate | Fosun Pharma | phase 2 | 1 |
| ALK Molecular Glue Degrader TRI-611rule | triana-biomedicines-inc | phase 2 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan | 1 | Recruiting | Aug 31, 2030 | 102 |
How it is read
Names in the registry
- “AQUA07”, 1 entry
Codes read as this program: AQUA07.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.